Drug Approval | May 30, 2024
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Subscribe To Our Newsletter & Stay Updated
